• Wion
  • /World
  • /Remdesivir did not cut hospital stay or mortality in virus patients: WHO

Remdesivir did not cut hospital stay or mortality in virus patients: WHO

Remdesivir did not cut hospital stay or mortality in virus patients: WHO

Remdesivir for coronavirus

The World Health Organization (WHO) has said that remdesivir has had little or no effect on coronavirus patients' length of hospital stay or chances of survival.

Also Read |Young person might have to wait until 2022 to get vaccine, saysWHO scientist

The drug was recently used to treat US President Donald Trump after he was detected with the virus. The US president had completed two doses of therapeutic drug remdesivir, according to White House doctor Sean Conley which he was administered soon after he arrived at the Walter Reed hospital.

Add WION as a Preferred Source

There is a global shortage for remdesivir which is known to be an expensive drug. The US Food and Drug Administration(FDA) had earlier granted emergency use authorization(EUA) for the antiviral remdesivir for convalescent plasma and for hydroxychloroquine. It has been authorised in several countries.

Canada had earlier allowed remdesivir to be used for patients with severe coronavirus symptoms. It was the first drug that Canada had authorized for the treatment of COVID-19 patients. In July, the European Commission had authorized the use of remdesivir to treat the virus.

Remdesivir was earlier intended as a treatment for Ebola.

About the Author